The News: It’s been a few years since the US government unveiled its Open Payments (OP) database, a collection of drug and device makers’ payments to healthcare providers. The data-collection… Read more »
The Food and Drug Administration on Tuesday (June 27, 2017) moved to try to spur more competition in the market for generic drugs, an effort aimed at driving down prices. In… Read more »
Steve’s Take: [“Life is far too short to spend it immersed in an unhealthy relationship.”—Jeffrey M. Cohen, Esq., professional mediator.] This week (March 13, 2017), billionaire Bill Ackman exited one… Read more »
The News: Valeant Pharmaceuticals International Inc.’s (Laval Quebec) fourth-quarter loss widened to $515 million versus $385 million in the same period of 2015, as sales plummeted 13% year-over-year to $2.4… Read more »
Valeant Pharmaceuticals International Inc. (Laval Quebec) is selling its Dendreon cancer treatment business and three skincare brands for $2.12 billion as the troubled Canadian drugmaker looks to reduce more than… Read more »
Valeant Pharmaceuticals International Inc.’s (Laval Québec) talks to sell a stomach-drug business to Japan’s Takeda Pharmaceutical Co. (Osaka) for roughly $10 billion have broken down amid last-minute disagreements over price and other matters,… Read more »
Shares of Arrowhead Pharmaceuticals Inc. (Pasadena CA) cratered 69% to $1.44 last week (November 28 to December 2, 2016) after the company said it would stop developing all drugs being… Read more »
Federal prosecutors filed charges against former Valeant Pharmaceuticals International Inc. (Laval Québec) executive Gary Tanner and former Philidor Rx Services LLC (Hatboro PA) CEO Andrew Davenport, alleging they engaged in… Read more »
After an already noisy year, Valeant Pharmaceuticals International Inc. (Laval Québec) once again took investors off guard–this time, on Election Day–as new management cut the annual profit forecast to well… Read more »
Valeant Pharmaceuticals International Inc. (Laval Quebec) is in advanced talks to sell a big stomach-drug business to Japan’s Takeda Pharmaceutical Co. for about $10 billion, a move seen easing pressure on Valeant over its… Read more »
